PURPOSE: To determine whether hypertriglyceridemia is associated with systemic
inflammation, which may contribute to the increased cardiovascular risk in patients who …

OBJECTIVE: To examine the effects of fenofibrate (160mg/d) therapy on fasting and
postprandial cytokine production in subjects with metabolic syndrome and …

OBJECTIVE—The aim of this study was to determine the effects of fenofibrate (160 mg/day)
on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in …

Context: Fenofibrate is a peroxisome proliferator-activated receptor α agonist widely used in
clinical practice, but its mechanism of action is incompletely understood. Objective: The aim …

Background: Atherosclerosis is the leading cause of death in developed countries. Although
the mechanisms that underlie this process are not well defined, it has been proposed that …

Recent data from Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial
(VA-HIT) have recently reported that pharmacological treatment with a fibrate (gemfibrozil) …

Background Development of insulin resistance (IR) may be important in the pathogenesis of
both metabolic syndrome and type 2 diabetes mellitus. Few data are available regarding the …

Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …

Context: Apart from lowering lipid levels, peroxisome proliferator-activated receptor (PPAR)
α activators (fibrates) produce many other favorable effects that may contribute to their …

We examined cellular membrane fatty acid composition and insulin sensitivity in patients
with mild essential hypertension and hyperlipidemia, and investigated whether bezafibrate …